Gyre Therapeutics (GYRE) Long-Term Investments (2010 - 2025)
Gyre Therapeutics (GYRE) posted quarterly Long-Term Investments of $107.1 million for Q4 2025, up 66.46% year-over-year from $64.3 million in Q4 2024, and up 66.46% quarter-over-quarter from $64.3 million in Q4 2024.
Gyre Therapeutics (GYRE) Long-Term Investments (2010 - 2025) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Long-Term Investments for 11 consecutive years, with $107.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Investments rose 66.46% year-over-year to $107.1 million; the TTM figure through Dec 2025 stood at $107.1 million (up 66.46% YoY), while the FY2025 annual figure was $107.1 million, up 66.46% from the prior year.
- Long-Term Investments climbed to $107.1 million in Q4 2025 per GYRE's latest filing, from $64.3 million in the prior quarter.
- Across five years, Long-Term Investments topped out at $107.1 million in Q4 2025 and bottomed at $40.6 million in Q4 2022.
- Historically, Long-Term Investments has averaged $65.4 million across 4 years, with a median of $57.0 million in 2023.
- Annual changes were most pronounced in 2023 — Long-Term Investments grew 22.34% — and 2025, when it jumped 66.46%.
- Gyre Therapeutics' Long-Term Investments stood at $40.6 million in 2022, then gained by 22.34% to $49.7 million in 2023, then rose by 29.38% to $64.3 million in 2024, then soared by 66.46% to $107.1 million in 2025.
- Business Quant data shows GYRE's Long-Term Investments at $107.1 million in Q4 2025, $64.3 million in Q4 2024, and $49.7 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 372.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.17 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 107.05 Mn |
| Dec 31, 2024 | 64.31 Mn |
| Dec 31, 2023 | 49.71 Mn |
| Dec 31, 2022 | 40.63 Mn |
| Dec 31, 2020 | 2.54 Mn |
| Sep 30, 2020 | 1.17 Mn |
| Sep 30, 2015 | 825,000.00 |
| Jun 30, 2015 | 828,000.00 |
| Mar 31, 2015 | 1.52 Mn |
| Dec 31, 2014 | 3.42 Mn |
| Sep 30, 2014 | 16.63 Mn |
| Jun 30, 2014 | 25.12 Mn |
| Mar 31, 2014 | 34.90 Mn |
| Dec 31, 2013 | 51.45 Mn |
| Sep 30, 2013 | 58.36 Mn |
| Jun 30, 2013 | 63.81 Mn |
| Mar 31, 2013 | 65.22 Mn |
| Dec 31, 2012 | 59.97 Mn |
| Sep 30, 2012 | 51.91 Mn |
| Jun 30, 2012 | 49.41 Mn |